Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

76
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
76
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The IMPACT-FH Renewal Protocol: Evaluating FH Cascade Testing Implementation in Primary Care through a Pragmatic Trial, Economic Evaluation, and Mixed-Methods Sustainability Assessment.

Public health genomics·2026
Same author

Electronic Health Record Alerts to Improve Lipid Lowering After a Recent Myocardial Infarction.

Journal of the American Heart Association·2026
Same author

A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals.

Circulation·2026
Same author

Improving adherence to guideline-based lipid-lowering therapy in people with hyperlipidemia using a targeted educational outreach approach.

Journal of managed care & specialty pharmacy·2026
Same author

Rationale and design of the Corrie Lipids Program: Impact of a digital health-enabled implementation initiative to improve lipid management.

American heart journal·2026
Same author

Variation in Lipid Management for Atherosclerotic Cardiovascular Disease Across US Health Systems.

Circulation. Population health and outcomes·2026

関連する実験動画

Updated: Sep 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

動脈硬化性心血管疾患の患者における脂質低下療法と心血管結果: 系統的レビューとメタ解析

Laney K Jones1, Cara East2, Om P Ganda3

  • 1Department of Genomic Health Research Institute, Geisinger Danville PA USA.

Journal of the American Heart Association
|August 29, 2025
PubMed
まとめ

血脂低下療法 (LLT) の適用は,動脈硬化性心血管疾患 (ASCVD) の患者の心血管疾患を著しく減少させる. LLTの順守を向上させることは,患者の改善と主要な心血管疾患の予防に不可欠です.

キーワード:
粘着性動脈硬化性心血管疾患脂質低下療法持続性スタチン

さらに関連する動画

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

関連する実験動画

Last Updated: Sep 9, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

科学分野:

  • 心臓病科
  • 公衆衛生
  • 薬理学について

背景:

  • 低密度脂質タンパク質コレステロール (LDL-C) の持続的な高さは,動脈硬化性心血管疾患 (ASCVD) の主要な危険因子です.
  • 脂質低下療法 (LLT) が利用可能であるにも関わらず,多くのASCVD患者は目標のLDL- Cレベルに達することができません.
  • LLTの不十分な遵守は,LDL-Cの目標を達成する上で重要な障壁であり,心血管疾患の結果を悪化させる可能性があります.

研究 の 目的:

  • LLTと心血管疾患との関係を体系的に検討し,メタ分析する.
  • ASCVD患者の死亡率と主要な不良心血管事件に対するLLT遵守の影響を明らかにする.

主な方法:

  • 2023年3月に主要なデータベース (PubMed,Embase,Scopus,CINAHL) で体系的な文献検索が行われました (2024年9月更新).
  • 対象となったのは,臨床ASCVDの成人の観察研究で,客観的なLLT適合度および心血管疾患のアウトカムが報告された.
  • バイアスのリスクは,研究と情報翻訳による臨床的進歩ツールを使用して評価されました.

主要な成果:

  • メタアナリシスには39件の研究が含まれており,主にスタチンの服用期間 (≥80%の値) によって測定されたスタチンの服用期間に焦点を当てた.
  • すべての原因による死亡リスク (HR,0. 56) と主要心血管疾患の有害事象 (HR,0. 77) の統計的に有意な減少と関連していた.
  • 心筋梗塞の有意な減少 (HR,0. 86) も観察され,心血管疾患による死亡と不全性脳卒中では有意な傾向が見られた.

結論:

  • 臨床ASCVDと診断された患者において,脂質低下療法への遵守は,心血管疾患のリスクの低下と有意に関連しています.
  • これらの発見は,よりよい心血管リスク管理のためにLLTの遵守を改善するための戦略の重要性を強調しています.